Percutaneous radiofrequency ablation of renal tumors: Technique, limitations, and morbidity

Kenneth Ogan, Lucas Jacomides, Bart L. Dolmatch, Frank J. Rivera, Marco F. Dellaria, Shellie C Josephs, Jeffrey A Cadeddu

Research output: Contribution to journalArticle

131 Citations (Scopus)

Abstract

Objectives. To evaluate our evolving experience with percutaneous radiofrequency (RF) renal tumor ablation and focus on our technique to ensure maximal treatment efficacy and reduce the possibility of complications. Methods. Fifteen patients with small (less than 4 cm) posterior or lateral contrast-enhancing (more than 10 Hounsfield units) renal tumors were candidates for RF treatment. Of these patients, 12 (13 tumors) received computed tomography-guided percutaneous RF ablation. General anesthesia was administered in all but our first 2 patients, who received intravenous sedation. After treatment, patients were closely followed up with computed tomography scans at 6 weeks and 3, 6, and 12 months, and every 6 months thereafter. Successful ablation was defined as a lesion along with a margin of normal parenchyma that no longer enhanced (less than 10 Hounsfield units) on follow-up contrast imaging. Results. The mean tumor size was 2.4 ± 0.6 cm. The average procedure time was 95 minutes (range 60 to 150) and length of stay 0.9 days. All patients underwent the procedure without any major complications. At a mean follow-up of 4.9 months, 12 (93%) of 13 tumors were successfully ablated. In 3 patients, the procedure was not performed because of intervening bowel or lung parenchyma when positioned in the prone position before the procedure. Conclusions. Computed tomography-guided percutaneous RF ablation of small renal tumors is a viable minimally invasive treatment option with a high short-term success rate and low morbidity. This new technology must be uniformly applied to assess its long-term efficacy.

Original languageEnglish (US)
Pages (from-to)954-958
Number of pages5
JournalUrology
Volume60
Issue number6
DOIs
StatePublished - Dec 1 2002

Fingerprint

Morbidity
Kidney
Neoplasms
Tomography
Prone Position
General Anesthesia
Length of Stay
Therapeutics
Technology
Lung

ASJC Scopus subject areas

  • Urology

Cite this

Ogan, K., Jacomides, L., Dolmatch, B. L., Rivera, F. J., Dellaria, M. F., Josephs, S. C., & Cadeddu, J. A. (2002). Percutaneous radiofrequency ablation of renal tumors: Technique, limitations, and morbidity. Urology, 60(6), 954-958. https://doi.org/10.1016/S0090-4295(02)02096-4

Percutaneous radiofrequency ablation of renal tumors : Technique, limitations, and morbidity. / Ogan, Kenneth; Jacomides, Lucas; Dolmatch, Bart L.; Rivera, Frank J.; Dellaria, Marco F.; Josephs, Shellie C; Cadeddu, Jeffrey A.

In: Urology, Vol. 60, No. 6, 01.12.2002, p. 954-958.

Research output: Contribution to journalArticle

Ogan, K, Jacomides, L, Dolmatch, BL, Rivera, FJ, Dellaria, MF, Josephs, SC & Cadeddu, JA 2002, 'Percutaneous radiofrequency ablation of renal tumors: Technique, limitations, and morbidity', Urology, vol. 60, no. 6, pp. 954-958. https://doi.org/10.1016/S0090-4295(02)02096-4
Ogan K, Jacomides L, Dolmatch BL, Rivera FJ, Dellaria MF, Josephs SC et al. Percutaneous radiofrequency ablation of renal tumors: Technique, limitations, and morbidity. Urology. 2002 Dec 1;60(6):954-958. https://doi.org/10.1016/S0090-4295(02)02096-4
Ogan, Kenneth ; Jacomides, Lucas ; Dolmatch, Bart L. ; Rivera, Frank J. ; Dellaria, Marco F. ; Josephs, Shellie C ; Cadeddu, Jeffrey A. / Percutaneous radiofrequency ablation of renal tumors : Technique, limitations, and morbidity. In: Urology. 2002 ; Vol. 60, No. 6. pp. 954-958.
@article{77e40d422957425998703f6e5d117786,
title = "Percutaneous radiofrequency ablation of renal tumors: Technique, limitations, and morbidity",
abstract = "Objectives. To evaluate our evolving experience with percutaneous radiofrequency (RF) renal tumor ablation and focus on our technique to ensure maximal treatment efficacy and reduce the possibility of complications. Methods. Fifteen patients with small (less than 4 cm) posterior or lateral contrast-enhancing (more than 10 Hounsfield units) renal tumors were candidates for RF treatment. Of these patients, 12 (13 tumors) received computed tomography-guided percutaneous RF ablation. General anesthesia was administered in all but our first 2 patients, who received intravenous sedation. After treatment, patients were closely followed up with computed tomography scans at 6 weeks and 3, 6, and 12 months, and every 6 months thereafter. Successful ablation was defined as a lesion along with a margin of normal parenchyma that no longer enhanced (less than 10 Hounsfield units) on follow-up contrast imaging. Results. The mean tumor size was 2.4 ± 0.6 cm. The average procedure time was 95 minutes (range 60 to 150) and length of stay 0.9 days. All patients underwent the procedure without any major complications. At a mean follow-up of 4.9 months, 12 (93{\%}) of 13 tumors were successfully ablated. In 3 patients, the procedure was not performed because of intervening bowel or lung parenchyma when positioned in the prone position before the procedure. Conclusions. Computed tomography-guided percutaneous RF ablation of small renal tumors is a viable minimally invasive treatment option with a high short-term success rate and low morbidity. This new technology must be uniformly applied to assess its long-term efficacy.",
author = "Kenneth Ogan and Lucas Jacomides and Dolmatch, {Bart L.} and Rivera, {Frank J.} and Dellaria, {Marco F.} and Josephs, {Shellie C} and Cadeddu, {Jeffrey A}",
year = "2002",
month = "12",
day = "1",
doi = "10.1016/S0090-4295(02)02096-4",
language = "English (US)",
volume = "60",
pages = "954--958",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Percutaneous radiofrequency ablation of renal tumors

T2 - Technique, limitations, and morbidity

AU - Ogan, Kenneth

AU - Jacomides, Lucas

AU - Dolmatch, Bart L.

AU - Rivera, Frank J.

AU - Dellaria, Marco F.

AU - Josephs, Shellie C

AU - Cadeddu, Jeffrey A

PY - 2002/12/1

Y1 - 2002/12/1

N2 - Objectives. To evaluate our evolving experience with percutaneous radiofrequency (RF) renal tumor ablation and focus on our technique to ensure maximal treatment efficacy and reduce the possibility of complications. Methods. Fifteen patients with small (less than 4 cm) posterior or lateral contrast-enhancing (more than 10 Hounsfield units) renal tumors were candidates for RF treatment. Of these patients, 12 (13 tumors) received computed tomography-guided percutaneous RF ablation. General anesthesia was administered in all but our first 2 patients, who received intravenous sedation. After treatment, patients were closely followed up with computed tomography scans at 6 weeks and 3, 6, and 12 months, and every 6 months thereafter. Successful ablation was defined as a lesion along with a margin of normal parenchyma that no longer enhanced (less than 10 Hounsfield units) on follow-up contrast imaging. Results. The mean tumor size was 2.4 ± 0.6 cm. The average procedure time was 95 minutes (range 60 to 150) and length of stay 0.9 days. All patients underwent the procedure without any major complications. At a mean follow-up of 4.9 months, 12 (93%) of 13 tumors were successfully ablated. In 3 patients, the procedure was not performed because of intervening bowel or lung parenchyma when positioned in the prone position before the procedure. Conclusions. Computed tomography-guided percutaneous RF ablation of small renal tumors is a viable minimally invasive treatment option with a high short-term success rate and low morbidity. This new technology must be uniformly applied to assess its long-term efficacy.

AB - Objectives. To evaluate our evolving experience with percutaneous radiofrequency (RF) renal tumor ablation and focus on our technique to ensure maximal treatment efficacy and reduce the possibility of complications. Methods. Fifteen patients with small (less than 4 cm) posterior or lateral contrast-enhancing (more than 10 Hounsfield units) renal tumors were candidates for RF treatment. Of these patients, 12 (13 tumors) received computed tomography-guided percutaneous RF ablation. General anesthesia was administered in all but our first 2 patients, who received intravenous sedation. After treatment, patients were closely followed up with computed tomography scans at 6 weeks and 3, 6, and 12 months, and every 6 months thereafter. Successful ablation was defined as a lesion along with a margin of normal parenchyma that no longer enhanced (less than 10 Hounsfield units) on follow-up contrast imaging. Results. The mean tumor size was 2.4 ± 0.6 cm. The average procedure time was 95 minutes (range 60 to 150) and length of stay 0.9 days. All patients underwent the procedure without any major complications. At a mean follow-up of 4.9 months, 12 (93%) of 13 tumors were successfully ablated. In 3 patients, the procedure was not performed because of intervening bowel or lung parenchyma when positioned in the prone position before the procedure. Conclusions. Computed tomography-guided percutaneous RF ablation of small renal tumors is a viable minimally invasive treatment option with a high short-term success rate and low morbidity. This new technology must be uniformly applied to assess its long-term efficacy.

UR - http://www.scopus.com/inward/record.url?scp=0036899075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036899075&partnerID=8YFLogxK

U2 - 10.1016/S0090-4295(02)02096-4

DO - 10.1016/S0090-4295(02)02096-4

M3 - Article

C2 - 12475648

AN - SCOPUS:0036899075

VL - 60

SP - 954

EP - 958

JO - Urology

JF - Urology

SN - 0090-4295

IS - 6

ER -